IMCR FY2025 SEC EDGAR DEF 14A #46 of 168 in industry

Immunocore Holdings plc CEO pay ratio

The CEO earned $10.8M in FY2025 against median worker pay of $117,720 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
X0
Filing date
2026-04-16
Industry
Chemicals & Pharmaceuticals
Industry rank
#46/168

Data updated August 2026

Subscribe to Immunocore Holdings plc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
92:1
Moderate (Scale: 0–1000:1)
CEO pay
$10.8M
Median worker
$117,720

Answer first

Immunocore Holdings plc's FY2025 CEO total of $10.8M ranks #479 of 1,423 complete filings; its 92:1 pay ratio ranks #685. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $117,720. Industry placement uses the FY2025 SIC-28 peer cohort (# 46 of 168, 73rd percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#479
$10.8M of 1,423 FY2025
Ratio rank
#685
92:1 of 1,423
Industry pct
73rd
above the industry median pay ratio

How Immunocore Holdings plc ranks nationally

Immunocore Holdings plc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$10,830,240 Top 34% higher than 66% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). This entry sits in this band. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Immunocore Holdings plc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($10.8M) against pay ratio (92:1) for Immunocore Holdings plc (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both4408911.510526525.81664414022761754.328879368.539.2:154.6:170:185.4:1100.8:1CEO total payPay ratio (CEO : median worker)Immunocore Holdings plc, CEO total pay: 10830240 · Pay ratio (CEO : median worker): 92:1Immunocore Holdings plcPERRIGO Co plc, CEO total pay: 9026290 · Pay ratio (CEO : median worker): 91:1PERRIGO Co plcXencor Inc, CEO total pay: 5521205 · Pay ratio (CEO : median worker): 95:1Xencor IncCogent Biosciences, Inc., CEO total pay: 27767075 · Pay ratio (CEO : median worker): 95:1Cogent Biosciences, Inc.Moderna, Inc., CEO total pay: 20029717 · Pay ratio (CEO : median worker): 89:1Moderna, Inc.Hexcel Corp /de/, CEO total pay: 7252875 · Pay ratio (CEO : median worker): 98:1Hexcel Corp /de/
Immunocore Holdings plc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Immunocore Holdings plc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Immunocore Holdings plc

Complete DEF 14A pay-ratio filings for this CIK across FY2023–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
92:1
FY2025
vs prior FY
-27:1
from FY2024 119:1
CEO $ YoY
-16%
$10.8M latest
Filings shown
3
FY2023–2025
Immunocore Holdings plc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2023 $11.6M - $102,154 114:1 -
2024 $12.9M +10% $107,990 119:1 +5:1
2025 $10.8M -16% $117,720 92:1 -27:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1671927, FY2023–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
92:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$10.8M
Companies in Industry
168
vs. Industry Median
Above
#46 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Immunocore Holdings plc: MID · HEAVY pay ratio

Immunocore Holdings plc's FY2025 ratio 92:1 ranks #46 of 168 Chemicals & Pharmaceuticals filers (73rd percentile). the CEO earned 92× the median employee ($117,720) in FY2025.

Median employee $117,720 (HIGH-MED); MID · HEAVY stamps put about 92 median-wage years per CEO year.

CEO Total Pay

$10.8M

FY2025 Summary Compensation, above median

Pay Ratio

92:1

Near industry median

Immunocore Holdings plc in the higher Chemicals & Pharmaceuticals third

Immunocore Holdings plc's FY2025 ratio 92:1 ranks #46 of 168 Chemicals & Pharmaceuticals filers (73rd percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Immunocore Holdings plc's $10.8M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #479 and ratio rank #685 split - treat 92:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$10.8M
Median Employee Pay
$117,720
Pay Ratio
92:1
Filing Date
2026-04-16

Company Info

Ticker
IMCR
CIK
1671927
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
X0
View SEC filings →
SEC EDGAR DEF 14A for CIK 1671927, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Immunocore Holdings plc's FY2025 ratio 92:1 ranks #46 of 168 Chemicals & Pharmaceuticals filers (73rd percentile).

Read with Immunocore Holdings plc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · HEAVY · HIGH-MED.

Sinclair, Inc. · HEAVY

ABS(ceo_total_comp) peer at $10.8M (Δ $6K lighter vs Immunocore Holdings plc); STEEP · PAR-MED vs this page's MID · HEAVY · HIGH-MED.
Mccormick & Co Inc · HEAVY

ABS(ceo_total_comp) peer at $10.8M (Δ $7K lighter vs Immunocore Holdings plc); STEEP · PAR-MED vs this page's MID · HEAVY · HIGH-MED.
Calix, Inc · HEAVY

ABS(ceo_total_comp) peer at $10.8M (Δ $10K lighter vs Immunocore Holdings plc); FLOOR · ELITE-MED vs this page's MID · HEAVY · HIGH-MED.
Wolverine World Wide Inc /de/ · HEAVY

ABS(ceo_total_comp) peer at $10.8M (Δ $14K heavier vs Immunocore Holdings plc); STEEP · PAR-MED vs this page's MID · HEAVY · HIGH-MED.
PERRIGO Co plc (SIC 28 pole)

PERRIGO Co plc stamps MID · HEAVY nearest in-SIC by ABS(pay_ratio) to Immunocore Holdings plc's MID filing.
National dual ranks · #479/#685

Immunocore Holdings plc's FY2025 package sits #479 by CEO dollars and #685 by ratio under HEAVY · MID.
Comp structure · HEAVY

Immunocore Holdings plc's HEAVY CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Immunocore Holdings plc (CIK 1671927), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.